Novo Nordisk on Wednesday posted second-quarter operating profit below expectations, raised its 2024 sales forecast but trimmed profit outlook, as competition from Eli Lilly in the booming weight-loss drug market intensifies.
Operating profit in the quarter rose 8 per cent at constant exchange rates to 25.9 billion Danish crowns (€3.5 billion) compared with the 27.3 billion forecast by analysts in a LSEG poll and Novo’s Frankfurt-listed shares fell 3.2 per cent just after market opening.
The Danish company, which employs about 450 people in Ireland, said it now expected sales growth this year of between 22 per cent and 28 per cent in local currencies, compared with the previously guided range for 19 per cent to 27 per cent growth.
“We are pleased with the sales growth in the first half of 2024, which has enabled us to raise the outlook for the full year,” chief executive Lars Fruergaard Jorgensen said in a statement.
Stealth sackings: why do employers fire staff for minor misdemeanours?
How much of a threat is Donald Trump to the Irish economy?
MenoPal app offers proactive support to women going through menopause
Ezviz RE4 Plus review: Efficient budget robot cleaner but can suffer from wanderlust under the wrong conditions
But the company lowered its forecast for operating profit growth this year, to between 20 per cent and 28 per cent in local currencies, compared with its previous forecast of 22 per cent to 30 per cent.
Novo ended an advanced kidney disease trial in June, which resulted in an impairment loss of 5.7 billion Danish crowns, which the company said impacted operating profit.
The worse-than-expected second-quarter profits may deepen investor worries that Novo's first-mover advantage in the fast-growing obesity drug market is at risk.
Sales of Wegovy, Novo’s first-to-market weight-loss drug, also came in weaker than expected. Sales rose 53 per cent to 11.66 billion crowns compared with the 13.54 billion expected by analysts in a company-compiled consensus.
Some analysts forecast the obesity drug market could be worth about $150 billion by the early 2030s.
Investors are keen to hear from more from Novo – Europe’s most valuable listed company worth about $550 billion – on Wednesday about when it expects to significantly boost supplies of Wegovy in the United States and end shortages as rival Lilly swiftly builds market share.
The company is spending billions of dollars to increase production of Wegovy to meet runaway demand and fend off Lilly, which launched its rival therapy Zepbound in the US in December last year. – Reuters
